Natco Pharma’s marketing partner gets approval for Everolimus Tablets

08 Mar 2021

Natco Pharma’s marketing partner -- Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets (generic for Afinitor) from the U.S. Food and Drug Administration (USFDA).

NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks. The launch of 10mg strength of the product is subject to confidential terms of a settlement and license agreement entered into with the owner of the Afinitor brand.

The launch date of 10mg strength of the product will be announced at a later date. The above strengths of Everolimus are indicated in the treatment of breast cancer and a few other types of cancers. As per industry sales data, Afinitor and its therapeutic equivalents had generated annual sales of $712 million in USA during the twelve months ending December 2020.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Related Natco Pharma Ltd. Links:

Natco Pharma Share Price

921.85 10.25 (1.12%) Apr 16, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 646.05
Dr. Reddys Lab 4893.00
Lupin 1055.85
Piramal Enterprises 1719.50
Cadila Healthcare 527.00
View more..
Sensex vs Natco Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback